Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-11-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study. In Phase 1b, subjects will know the treatment they are receiving.
Subjects will receive Erlotinib + U3-1287. The Phase 1b portion will determine if adding
U3-1287 to Erlotinib will be safe in subjects with advanced non-small cell lung cancer who
fail prior treatment. In the Phase 2 portion, subjects will be blinded to the treatments they
are receiving. Subjects will receive either Erlotinib alone or Erlotinib + U3-1287.
The Phase 2 portion will determine if adding U3-1287 to Erlotinib will be safe and improve
survival in subjects with advanced non-small cell lung cancer who failed the first treatment.